education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Iklan
Iklan
MIMS home
Drugs
Info
Glauseta
Glauseta
acetazolamide
Manufacturer:
Sanbe Vision
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Acetazolamide
Indications/Uses
Open-angle glaucoma, secondary glaucoma & pre-op in angle-closure glaucoma.
Dosage/Direction for Use
Open-angle glaucoma
Initial dose: 250 mg 1-4 tab daily (in divided doses).
Secondary glaucoma & for lowering pre-op IOP
250 mg 4 hrly.
Childn
8-30 mg/kg daily.
Administration
Should be taken with food.
Contraindications
Marked kidney & liver disease/dysfunction, suprarenal gland & adrenal gland failure, hyperchloremic acidosis.
Special Precautions
Renal calculi, pulmonary obstruction, emphysema. Pregnancy & lactation. Childn.
Adverse Reactions
Paresthesia, hearing dysfunction/tinnitus, loss of appetite, taste alteration, GI disturbances eg, nausea, vomiting, diarrhea, polyuria, occasional drowsiness & confusion.
View
ADR Reporting Link
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01EC01 - acetazolamide ; Belongs to the class of carbonic anhydrase inhibitors. Used in the treatment of glaucoma.
Regulatory Classification
K
Presentation/Packing
Form
Glauseta tab 250 mg
Packing/Price
10 × 10's (Rp485,000/boks)
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk